Dr. Vimal Prajapati
Dr. Prajapati completed his dermatology residency at the University of Alberta, earning certification in both Canada and the United States. He then pursued an additional 1-year fellowship in pediatric dermatology at Harvard Medical School. Dr. Prajapati has received 20 major awards; authored 1 textbook chapter; published 43 peer-reviewed manuscripts in print or electronic format; and presented 48 abstracts at scientific meetings regionally, nationally, as well as internationally. He also conducts clinical trials for both adults and children, with participation in 69 studies as an investigator or steering committee member.
Dr. Prajapati is a Clinical Associate Professor at the University of Calgary as well as co-founder and co-director of Skin Health & Wellness Centre, Dermphi Centre, and Dermatology Research Institute. Additionally, he has started several subspecialty initiatives, including multidisciplinary pediatric morphea, pediatric scleroderma, and pediatric psoriasis clinics in Calgary as well as rapid access psoriasis and rapid access eczema clinics in Calgary plus rural outreach psoriasis and rural outreach eczema clinics Medicine Hat.
SAT Apr 29
Perspectives on psoriasis: Exploring what matters most to you
Objectives:
- Discuss the current state of psoriasis management by examining real world effectiveness of available treatments
- Provide an update on efficacy and safety data of bimekizumab in patients with moderate-to-severe plaque psoriasis
- Explore the impact that psoriasis and effective treatment has on the lives of patients with the disease
SAT Apr 29
Heads Up! A topline review of phase 3 clinical data in scalp psoriasis
Objectives:
After attending this program, attendees will be able to:
- Recognize current unmet needs and challenges in the management of scalp psoriasis
- Apply phase 3 trial data with tildrakizumab for the treatment of scalp psoriasis to clinical practice
- Identify patients with scalp psoriasis for whom tildrakizumab is appropriate
Session description:
Data from Phase 3 clinical trials prospectively evaluating currently available biologics in the treatment of scalp psoriasis are limited. In this session, Phase 3 trial data assessing the efficacy and safety of tildrakizumab in the treatment of moderate-to-severe psoriasis of the scalp will be presented. To demonstrate how the trial data can translate into the real-world, a patient case will be shared. The session will conclude with an opportunity for the audience to pose questions.
